Xeris Biopharma Holdings, Inc. Overview
Pro stress-test →Xeris Pharmaceuticals improves patient lives by developing and commercializing innovative, ready-to-use therapeutic medicines. As a commercial-stage biopharmaceutical company, it specializes in developing and commercializing therapies for chronic endocrine and neurological diseases. The company has built commercial momentum with three marketed products addressing significant patient populations.
Strategic Profile
Pro stress-test →Founded in 2005, Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. Key commercialized products include Recorlev, which ended 2025 with approximately 700 patients; Gvoke, which grew revenue more than 13% compared to prior year; and Keveyis, which finished with a growing patient base.
Competitive Landscape
Pro stress-test →Top competitors include UroGen Pharma, Marinus Pharmaceuticals, and Eagle Pharmaceuticals. Xeris differentiates through novel formulation platforms and focus on ready-to-use liquid-stable injectables in underserved therapeutic areas with limited competitive alternatives.
Industry Context
Xeris Biopharma Holdings, Inc. operates in Specialty Pharmaceuticals / Biopharmaceuticals.
Key facts
Founded: 2005 · Headquarters: Chicago, Illinois · Revenue: $266M · Market cap: $1.57B